Life Science Companies are Litigation Targets for Unhappy Investors Post author:Sam Post published:February 22, 2018 Post category:BioPharma Life science companies are popular targets for securities fraud litigation. Source: BioSpace You Might Also Like Adaptimmune Announces Closing Of $42 Million Registered Direct Offering April 10, 2017 San Diego's Arena Soars as Phase II Hypertension Trial Data Wows July 10, 2017 Dova Pharma Reports Second Quarter 2017 Operating and Financial Results August 10, 2017
